Anti-cancer screening of herbal drugs using cancer patient cells
Since the 1980s, a total of 174 new anti-cancer compounds have been approved for commercialization, of which 93 (53%) were natural products, or derived directly from plants. One of the most famous anti-cancer drugs, paclitaxel, used for the treatment of breast cancer, was isolated from the bark of Taxus Brevifolia. There is tremendous opportunity to systematically investigate promising plants and extracts for their anti-cancer activity and validate it rigorously in drug discovery campaigns. Even traditional plant-based medicines that have been in use for years need more data to claim anti-cancer activity. We provide a platform to pharma and biotech companies for screening their plant extracts and compounds directly on patient tumor-derived primary cancer cells (PDCs), in 2D and 3D assays, to confirm and compare their activity prior to testing in xenograft and PDX models.
Since the 1980s, a total of 174 new anti-cancer compounds have been approved for commercialization, of which 93 (53%) were natural products, or derived directly from plants. One of the most famous anti-cancer drugs, paclitaxel, used for the treatment of breast cancer, was isolated from the bark of Taxus Brevifolia. There is tremendous opportunity to systematically investigate promising plants and extracts for their anti-cancer activity and validate it rigorously in drug discovery campaigns. Even traditional plant-based medicines that have been in use for years need more data to claim anti-cancer activity. We provide a platform to pharma and biotech companies for screening their plant extracts and compounds directly on patient tumor-derived primary cancer cells (PDCs), in 2D and 3D assays, to confirm and compare their activity prior to testing in xenograft and PDX models.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Our Model of Working
We are working on drug discovery programs for US-based clients already to analyze the
anti-cancer property of their plant-based natural extracts, their mechanism of action and
toxicity determination in actual cancer patient tissue-derived cell models. This is being
done to validate their extracts prior to taking them for animal efficacy and into human
trials since patient samples have higher translation to clinical activity
We work as a CRO to design and execute the whole experimental plan to help clients for
their drug evaluation, strategic development plan in vivo, publication and/or patent
review and indications for clinical trials. IP belongs to the client.
We also consider collaborative projects on a case-by-case basis.
We are flexible and work as per each client’s requirement
13
11 July 2020
Sapien Biosciences
Change language